Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2009 by Asociacion Doctor Peset Para el Estudio de la Hematología.
Recruitment status was:  Recruiting
Pivotal S.L.
Information provided by:
Asociacion Doctor Peset Para el Estudio de la Hematología Identifier:
First received: February 20, 2009
Last updated: NA
Last verified: February 2009
History: No changes posted
The purpose of this study is to evaluate the efficacy (and safety) of the following treatment squeme:Ciclophosphamide, Vincristine, lyposomal Doxorrubicine (Myocet) and Prednisone,combined with Rituximab in first line treatment for patients with aggresive No Hodgkin B lymphoma and cardiovascular risk

Condition Intervention Phase
No Hodgkin B Lymphoma
Drug: RCOMP-14 + rituximab
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II, Multicenter Trial to Evaluate the Efficacy and Safety of the Following Treatment Squeme:Ciclophosphamide, Vincristine, Lyposomal Doxorrubicine, Myocet and Prednisone,Combined With Rituximab in First Line Treatment for Patients With Aggresive No Hodgkin B Lymphoma and Cardiovascular Risk

Resource links provided by NLM:

Further study details as provided by Asociacion Doctor Peset Para el Estudio de la Hematología:

Primary Outcome Measures:
  • Evaluate treatment efficacy by measuring response to treatment [ Time Frame: at the end of study ]

Secondary Outcome Measures:
  • evaluate cardiotoxicity and tolerability [ Time Frame: At the end of study ]
  • Evaluate progression free survival [ Time Frame: At the end of study ]
  • Evaluate event free survival [ Time Frame: At the end of study ]
  • Evaluate tumor free survival [ Time Frame: At the end of study ]
  • Evaluate overall survival [ Time Frame: At the end of study ]
  • Evaluate response duration [ Time Frame: At the end of study ]
  • treatment adherence [ Time Frame: At the end of study ]
  • time to progression [ Time Frame: At the end of the study ]
  • dose intensity and relative dose intensity [ Time Frame: At the end of the study ]

Estimated Enrollment: 44
Study Start Date: August 2008
Estimated Study Completion Date: November 2010
Estimated Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: unique
RCOMP-14 with Rituximab
Drug: RCOMP-14 + rituximab

Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.

Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d.

Detailed Description:
Phase II, multicenter, open , 1-arm study.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with histological diagnosis of Lymphoma no Hodgkin B CD20+ high degree of mailgnancy
  2. Patients no previously treated
  3. stage III o IV
  4. Informed consent
  5. At least one measurable injury
  6. Age >18
  7. ECOG 0-2
  8. Life expectancy >6 months
  9. Cardiovascular risk defined as:Mild-moderate systolic dysfunction,isquemic cardiopathy, diabetes mellitus, hypertension,left ventricular hypertrophy, cardiac arrhythmia, moderate pulmonar hypertension
  10. adequate organic functionallity (creatinine<2mg/dl;bilirubin<2mg/dl; ALT-AST-FA<5 FSN; neutrphyls total count >1.5x 109/l and platellet count >100x1097l)
  11. Use of a contraceptive method during study + 3 months -

Exclusion Criteria:

  1. stage I or II with IPI=0
  2. Symptomatic tumoral affection of Nervous central system
  3. Lymphoma no hodgkin B indolent
  4. Lymphoma no hodgkin B mantle-cell
  5. Lymphoma no hodgkin T
  6. lymphoprolifertaive syndrome post-transplantation or immunosuppression associated
  7. cardiovacualr disease symptomatic
  8. Cronic infection or acute serious
  9. history of neoplasia in past 5 years
  10. not able to understand the study or poor protocol adherence
  11. Known Hypersensivity to any atudy drug
  12. pregnant/lactant women
  13. Previous participation in clinicla study in past 30 days
  14. Previous treatment with antraciclines or any drug used in this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00849355

Contact: Secundino Ferrer +34961622536
Contact: Felix Carbonell +34961972000

hospital del Mar Active, not recruiting
Barcelona, Spain, 08003
Hospital Vall D'Hebrón Active, not recruiting
Barcelona, Spain, 08035
Hospital de Castellon Active, not recruiting
Castellon, Spain, 12004
Hospital Severo Ochoa Not yet recruiting
Madrid, Spain, 28211
Contact: Pedro Sanchez    +34914818000   
Hospital Universitario Puerta de Hierro Active, not recruiting
Madrid, Spain, 28220
Hospital de Getafe Recruiting
Madrid, Spain
Contact: Jose García    +34916839360   
Hospital son Llatzer Active, not recruiting
Mallorca, Spain, 07198
Hospital Morales Messeguer Not yet recruiting
Murcia, Spain, 30008
Contact: Jose Sanchez    +34606388315   
Hospital Santa Mª del Rosell Not yet recruiting
Murcia, Spain, 30203
Contact: Antonio Martinez    +34968504800   
Hospital general universitario de Valencia Active, not recruiting
Valencia, Spain, 46014
H. Arnau de Vilanova Active, not recruiting
Valencia, Spain, 46015
Hospital Universitario Dr. Peset Active, not recruiting
Valencia, Spain, 46017
Sponsors and Collaborators
Asociacion Doctor Peset Para el Estudio de la Hematología
Pivotal S.L.
  More Information

Responsible Party: Secundino Ferrer, Asociacion Doctor Peset Para el Estudio de la Hematología Identifier: NCT00849355     History of Changes
Other Study ID Numbers: ADOPEH-LINFMYO-2007
Study First Received: February 20, 2009
Last Updated: February 20, 2009

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Immunologic Factors
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017